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Summary By analogy with combination chemotherapy, endocrine agents with different mechanisms of action
have been combined in the treatment of patients with advanced breast cancer. The clinical use of
tamoxifen +aminoglutethimide +hydrocortisone showed no clinical benefit over the individual use of
tamoxifen or aminoglutethimide +hydrocortisone. The endocrine changes occurring in postmenopausal
patients as a consequence of their treatment with tamoxifen+aminoglutethimide+hydrocortisone have been
examined. Suppression of gonadotrophin and oestrogen levels and increased levels of sex hormone binding
globulin were observed. These changes might be expected to be of benefilt in the treatment of advanced breast
cancer, and do not explain the lack of clinical benefit in combining the treatments.
Non-responders to this combination therapy had higher levels of oestrone and dehydroepiandrosterone
sulphate whilst on treatment than responders, confirming previous observations in patients treated with
aminoglutethimide +hydrocortisone.
There are now several options for the medical
endocrine treatment of advanced breast cancer in
postmenopausal women (Stoll, 1981). Response to
these individual agents occurs in about one third of
unselected patients. The incidence of response can
be increased by patient selection on the basis of
oestrogen receptor analyses (McGuire, 1980). It is
clear that a few patients will respond to one of
these agents having failed to respond to another
and, in addition, some patients who have relapsed
after responding to one agent may show a second
response to another (Smith et al., 1982). It has
therefore been postulated that combination of
endocrine medications might increase the response
rate and response duration as has been found with
combination chemotherapy.
We have previously demonstrated, however, that
treatment of patients with tamoxifen +
aminoglutethimide +hydrocortisone, has no
significant benefits in terms of response rate or
response duration over treatment with tamoxifen or
aminoglutethimide +hydrocortisone (Smith et al.,
1983). We have compared the endocrine changes
elicited by the combination in the circulation with
those known to occur with the individual
treatments, to determine whether the clinical
observations could be explained by any antagonism
between the agents. We have also related these
changes to tumour response, since this may enable
identification of those changes which are
particularly important to the growth of the tumour.
Patients and methods
Patients
Forty-six patients were studied from a previously
described clinical trial (Smith et al., 1982, 1983).
All patients had histologically proven advanced
breast cancer and none had received previous
endocrine therapy. They were treated until disease
progression with tamoxifen 10mg twice daily,
aminoglutethimide 250mg 3 times daily (increasing
to 4 times daily after 2 weeks if toxicity permitted)
and hydrocortisone 20mg twice daily. Response to
therapy was assessed according to standard UICC
criteria (Hayward et al., 1977). All patients were
classed as postmenopausal on the basis of no
menstrual bleed for at least 2 years and a
pretreatment follicle stimulating hormone (FSH)
level over 20IUI -1.
Bloodsamples
Blood was taken at the outpatient clinic prior to
treatment and between 1 and 4 months on
treatment at intervals determined by the clinical
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status of the patients. For each patient blood was
sampled at the same time of day throughout the
study. The resulting serum was stored at -20°C
until assay.
Endocrine investigations
Oestrone, oestradiol, dehydroepiandrosterone
sulphate (DHAS), androstenedione and prolactin
were measured by radioimmunoassay according to
previously described methodology [oestrone,
oestradiol, (Harris et al., 1983a); DHAS, (Harris, et
al., 1982); androstenedione, (Dowsett et al., 1984);
prolactin, (Dowsett et al., 1983)]. Cross-reaction of
tamoxifen in the oestradiol and oestrone assays was
10-4% and 10-3% respectively. Sex hormone
binding globulin (SHBG) binding capacity was
measured according to the method of Iqbal and
Johnson (Iqbal & Johnson, 1977). Luteinizing
hormone (LH) and FSH were measured by double
antibody radioimmunoassay using the Chelsea
LH/FSH Radioimmunoassay Kit, which is used by
over 25 centres in the United Kingdom (Ferguson
et al., 1982).
All samples from the same patient were analysed
in the same batch.
Analysis ofresults
In some patients multiple samples were available
for analysis but for statistical comparison the mean
of the results was taken. Differences between pre-
treatment and on-treatment samples were analyzed
by t-tests on paired data only, but the means given
include data from patients in which one or other
sample was missing. Differences between responders
and non-responders were analyzed by unpaired
t-tests.
Results
Effect of treatment on hormone levels:
Pretreatment hormone levels were compared with
the levels found between 1 and 4 months after
starting treatment (Table I). Mean levels of LH,
FSH, oestrone, oestradiol and DHAS were
suppressed on treatment but there were no
significant differences between pretreatment and on-
treatment levels of prolactin or androstenedione.
The mean percentage suppression was for LH 25%,
FSH 25%, oestrone 42%, oestradiol 71% and
DHAS 80%. SHBG levels on treatment were
significantly higher than pretreatment levels
showing a mean percentage increase of 66%.
Differences between responders and non-responders:
Those patients having stable disease on treatment
numbered only 5 and were therefore excluded from
the following comparisons. The pretreatment levels
of each hormone were compared between those
patients who responded and those with progressive
disease (Table IIA). The only significant difference
found was that the pretreatment level of DHAS
was lower in responders than in non-responders
(P=0.022).
Comparison during treatment of responders and
non-responders (Table IIB) showed a significantly
lower level of oestrone in responders than in non-
responders (P=0.004). No relationship was found
between oestrone levels and the incidence of
metastatic disease in particular sites. There was also
a lower mean level of DHAS in responders, which
was of marginal statistical significance (P '0.05).
No significant correlation was found in this study
between patient weight and either pretreatment or
on-treatment levels of either DHAS or oestrone.
Table I Hormone levels in postmenopausal patients before and during treatment. A4A: androstenedione. P
values relate to differences between pretreatment and on-treatment values
LH FSH Prolactin A4A Oestrone Oestradiol DHAS SHBG
IU-1 IUI-l1 mIU-lI nmol'-' pmol'-, pmolU' plmoll-' nmol'-
Pretreatment:
Mean 44.8 61.7 279 2.74 148 53.1 1.80 57.3
s.e. +2.7 +3.1 +55 +0.27 +7 +10.1 +0.21 +3.5
n 40 41 40 38 40 40 40 40
252 1.97
+22 +0.38
40 40
NS NS
82
+4
41
<0.001
11.8 0.39 81.8
+1.6 +0.09 +5.0
41 40 41
<0.001 <0.001 <0.001
On-treatment:
Mean
s.e.
n
p
32.2
+2.1
40
<0.001
43.8
+2.7
41
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Table II Hormone levels in post-menopausal responders and non-responders, A: before treatment, B:
during treatment. A4A: androstenedione. P values relate to differences between responders and non-
responders.
LH FSH Prolactin A4A Oestrone Oestradiol DHAS SHBG
IU1-' IUl-' mIU1' nmoll~' pmoll ' pmoll~' ymoll'l nmoll'
A. PRETREATMENT
Responders:
Mean 47.1 62.7 229 3.08 154 65.7 1.23 48.5
s.e. +5.9 +5.6 +35 +0.54 +15 +22.1 +0.19 +5.8
n 14 15 15 14 15 15 14 15
Non-responders:
Mean 42.6 60.1 307 2.55 157 49.1 2.30 60.6
s.e. +3.1 +4.5 +102 +0.27 +10 +11.1 +0.34 +4.2
n 21 21 21 19 21 21 21 19
P NS NS NS NS NS NS <0.05 NS
B. ON-TREATMENT
Responders:
Mean 30.9 43.1 241 1.40 70.6 12.0 0.22 78.2
s.e. +2.7 +4.5 +19 +0.26 +4.0 +2.3 +0.06 +6.6
n 19 19 19 19 19 19 19 19
Non-responders:
Mean 33.8 42.7 268 4.96 97.5 11.4 0.62 80.1
s.e. +3.8 +4.3 +43 +2.37 +8.1 +2.3 +0.20 +9.9
n 17 17 16 16 17 17 16 8
P NS NS NS NS <0.005 NS 0.05 NS
The mean time on treatment before sample for
responders was 59+5 (s.e.) days and for non-
responders was 51 +8 days.
There were no differences between responders
and non-responders in the effects of treatment on
hormone levels except in androstenedione levels
which were significantly suppressed in responders
(P=0.016, n= 14). In contrast, non-responders had
a higher mean level of androstenedione on-
treatment than before treatment, though high
between-patient variability led to the difference
being statistically non-significant.
Discussion
The major mechanism by which patients with
advanced breast cancer respond to endocrine agents
is thought to be by the suppression of oestrogen-
stimulated tumour growth (Stoll, 1981). Tamoxifen
is thought to act by blocking the interaction of
oestrogen with oestrogen receptors (McGuire, 1980)
whilst aminoglutethimide is believed to act by
suppressing oestrogen synthesis (Santen et al.,
1978). It is clear, however, that some patients who
fail to respond to one of these agents, will respond
to the other (Smith et al., 1982). Also many
patients who relapse subsequent to an initial
response to one of the drugs will go on to show a
second response to the other (Smith et al., 1982). It
is possible therefore that by combining the two
drugs, a greater proportion of patients might
respond and the response might be of longer
duration than with the individual agents given
separately. However, a clinical evaluation of the
combination showed no significant improvement
over the individual agents in response rate or
response duration (Smith et al., 1983). The
combination may therefore be disadvantageous in
that the opportunity for sequential treatment for a
second response after relapse from first-line
treatment is lost.
The endocrine effects of the combination were
largely those which might be expected from the
known action of the individual agents in
postmenopausal women. Gonadotrophin levels were
suppressed and SHBG levels were increased.
Tamoxifen has been found to cause such typically
oestrogenic changes (Coombes et al., 1982; Willis
et al., 1977; Sakai et al., 1978) whilst
aminoglutethimide+hydrocortisone has little effect
on gonadotrophins but may also increase SHBG
levels (Harris et al., 1983a). Oestrone, oestradiol
and DHAS levels were suppressed to levels similar
to those found in our previous studies of
aminoglutethimide+hydrocortisone (Harris et al.,360 M. DOWSETT et al.
1983a,b). Tamoxifen would not be expected to
affect the levels of these hormones (Coombes et al.,
1982; Golder et al., 1976), though it has been
suggested by one study that oestradiol levels were
increased by tamoxifen (Willis et al., 1977). Any
such effect clearly did not overcome the suppressive
effects of aminoglutethimide +hydrocortisone in
this study.
The changes in hormone levels associated with
tamoxifen may be considered in terms of benefit or
detriment to the suppression of oestrogen levels by
aminoglutethimide. The observed fall in
gonadotrophin levels may be of some benefit, but is
unlikely to be of importance, since little oestrogen
is derived from the ovary in postmenopausal
women (Vermeulen, 1976). Increased SHBG levels
result in decreases in the unbound, biologically
active fraction of oestradiol (Anderson, 1974).
These two effects would therefore be expected to
add to the suppression of oestrogen-stimulated
tumour growth, and cannot explain the lack of
clinical benefit from combining the agents.
Tamoxifen shows both oestrogenic and
antioestrogenic effects (Clark & Peck, 1979;
Rochefort et al., 1983; Wakeling et al., 1983). The
balance of these effects varies between tissues
(Clark & Peck, 1979) and even within the same cell
(Rochefort et al., 1983). In the immature rat uterus
tamoxifen shows greater oestrogenic activity in the
presence of low concentrations of oestrogen
(Wakeling et al., 1983), and our observations on
changes in hormone levels would concur with such
an oestrogenic effect in postmenopausal women. In
this respect, suppression of oestrogens by
aminoglutethimide below the already low
postmenopausal levels may not allow the
antioestrogenic activity of tamoxifen to be
expressed and the predominantly oestrogenic effect
in this situation may explain the lack of clinical
benefit from combining the therapies. It is notable
that the administration of tamoxifen with 4
hydroxyandrostenedione, another aromatase
inhibitor, was less effective in eliciting rat
mammary tumour regression than 4-
hydroxyandrostenedione alone (Brodie et al., 1983).
DHAS levels were higher in non-responders than
responders both before treatment and during
treatment. In two earlier studies of
aminoglutethimide +hydrocortisone in advanced
breast cancer no difference in pretreatment levels of
DHAS was observed between responders and non-
responders (Harris et al., 1983a; Santen et al.,
1982). However, a similar difference between
responders and non-responders was observed in on-
treatment samples from one of these studies
(Santen et al., 1982). The same study found a
significantly higher on-treatment level of
androstenedione in non-responders to amino-
glutethimide+hydrocortisone. Although results in
the present study did not confirm this observation
directly, a significant suppression of andro-
stenedione was observed in the responders which
did not occur in the non-responders.
The difference found in the on-treatment levels of
oestrone between responders and non-responders in
this study confirms our previous observation of a
higher on-treatment level of oestrone in non-
responders to aminoglutethimide +hydrocortisone
therapy (Harris et al., 1983a). In the latter study it
appeared that this may have been due to a
preponderance of patients with hepatic metastases
who had high oestrone values, and it was suggested
that this might be due to a poor clearance of
oestrone by the liver. In the present study we found
no relationship between any site of metastatic
disease and high oestrone levels. It has been
demonstrated that weight and oestrogen levels are
correlated in postmenopausal women (MacDonald
et al., 1978; Reed et al., 1979) but such a
relationship did not explain the relatively high
oestrone levels in non-responders. Our recent
observation (Dowsett et al., 1984) that oestrone
levels rise as responders to amino-
glutethimide +hydrocortisone therapy approach
clinical relapse confirms the relationship of high
oestrone levels with progressive disease.
These observations of an excess of adrenal
androgens and oestrone in non-responders to
treatment may be due to the continued progressive
disease of these patients and resultant stress-
stimulated adrenal activity. We have previously
demonstrated that the short ACTH test can
increase plasma levels of adrenal androgens in
patients treated with aminoglutethimide +
hydrocortisone (Harris et al., 1983c), and Bonfrer et
al. (1983) demonstrated in similar patients that
longer stimulation with exogenous ACTH can
cause increases in oestrone levels. In the context of
the present study the magnitude of the observed
difference in oestrone levels is unlikely to be of
biological importance to the tumour, since
tamoxifen is included in the therapeutic regime.
The difference between responders and non-
responders in pretreatment DHA-S levels is less
easily explained. We could find no evidence for a
weight-related excess of DHA-S in the non-
responders (Feher & Halmy, 1975). It is possible
that in the light of its moderate statistical
significance, this difference may have occurred by
chance.
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